MD Stock Overview
MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$19.28|
|52 Week High||US$35.68|
|52 Week Low||US$17.17|
|1 Month Change||-15.18%|
|3 Month Change||-20.20%|
|1 Year Change||-40.66%|
|3 Year Change||-23.00%|
|5 Year Change||-65.35%|
|Change since IPO||260.80%|
Recent News & Updates
MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|MD||US Healthcare||US Market|
Return vs Industry: MD underperformed the US Healthcare industry which returned 1.8% over the past year.
Return vs Market: MD underperformed the US Market which returned -15.1% over the past year.
|MD Average Weekly Movement||6.3%|
|Healthcare Industry Average Movement||10.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: MD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MD's weekly volatility (6%) has been stable over the past year.
About the Company
MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors.
MEDNAX Fundamentals Summary
|MD fundamental statistics|
Is MD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MD income statement (TTM)|
|Cost of Revenue||US$1.43b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.95|
|Net Profit Margin||4.20%|
How did MD perform over the long term?See historical performance and comparison
Is MEDNAX undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MD ($19.28) is trading below our estimate of fair value ($37.46)
Significantly Below Fair Value: MD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MD is poor value based on its Price-To-Earnings Ratio (20.3x) compared to the US Healthcare industry average (19.4x).
PE vs Market: MD is poor value based on its Price-To-Earnings Ratio (20.3x) compared to the US market (15.2x).
Price to Earnings Growth Ratio
PEG Ratio: MD is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: MD is good value based on its Price-To-Book Ratio (1.9x) compared to the US Healthcare industry average (2.5x).
How is MEDNAX forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MD's forecast earnings growth (10.6% per year) is above the savings rate (1.9%).
Earnings vs Market: MD's earnings (10.6% per year) are forecast to grow slower than the US market (13% per year).
High Growth Earnings: MD's earnings are forecast to grow, but not significantly.
Revenue vs Market: MD's revenue (6.9% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: MD's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MD's Return on Equity is forecast to be high in 3 years time
How has MEDNAX performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MD has a large one-off loss of $68.4M impacting its March 31 2022 financial results.
Growing Profit Margin: MD's current net profit margins (4.2%) are higher than last year (0.8%).
Past Earnings Growth Analysis
Earnings Trend: MD's earnings have declined by 45.9% per year over the past 5 years.
Accelerating Growth: MD's earnings growth over the past year (472.6%) exceeds its 5-year average (-45.9% per year).
Earnings vs Industry: MD earnings growth over the past year (472.6%) exceeded the Healthcare industry 9.6%.
Return on Equity
High ROE: MD's Return on Equity (9.3%) is considered low.
How is MEDNAX's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MD's short term assets ($439.8M) exceed its short term liabilities ($269.7M).
Long Term Liabilities: MD's short term assets ($439.8M) do not cover its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: MD's net debt to equity ratio (80.7%) is considered high.
Reducing Debt: MD's debt to equity ratio has increased from 68.7% to 91.8% over the past 5 years.
Debt Coverage: MD's debt is not well covered by operating cash flow (7.6%).
Interest Coverage: MD's interest payments on its debt are well covered by EBIT (4.2x coverage).
What is MEDNAX current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Ordan (62 yo)
Mr. Mark S. Ordan serves as Chief Executive Officer and Director at MEDNAX, Inc. since July 12, 2020. Mr. Ordan serves as a Director of The Carlyle Group Inc. since April 1, 2022. He joined MEDNAX, Inc. in...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD6.85M) is about average for companies of similar size in the US market ($USD5.40M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Experienced Management: MD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: MD's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MEDNAX, Inc.'s employee growth, exchange listings and data sources
- Name: MEDNAX, Inc.
- Ticker: MD
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$1.660b
- Shares outstanding: 86.12m
- Website: https://www.mednax.com
Number of Employees
- MEDNAX, Inc.
- 1301 Concord Terrace
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.